Skip to Main Content
Contribute Try STAT+ Today

Hello, everyone, and how are you today? Cloudy skies are hovering this morning over the Pharmalot campus, where the official mascot awaits a play date and the short person is, once again, sleeping in. As for us, we are engaged in the usual routines of readying our to-do list and brewing cups of stimulation. Our choice today, for those tracking such things, is southern pecan, all the way from New Orleans. Feel free to join us. Remember, no prescription is required, so no need to track rebates. Meanwhile, here are some tidbits. Hope you have a smashing day and, as always, do keep in touch. We appreciate your feedback and suggestions. …

The organization that negotiates supply contracts on behalf of more than 95% of the nation’s academic hospitals estimates its members are ordering just one to five vials of the controversial Biogen (BIIB) Alzheimer’s medicine each day, STAT reports. And another 15 university-affiliated hospitals are not offering the drug, including Johns Hopkins, the University of California, Los Angeles, and the University of Michigan. The disinterest in the drug is yet another blow to an already-catastrophic commercial rollout for the medicine, which the company had hoped would be a blockbuster product for the estimated 5.8 million Americans with Alzheimer’s.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment